Skip to contentI
Integra Lifesciences Holdings Corp
I
IARTIntegra Lifesciences Holdings Corp Source filing unavailable
Q2 2012 · —
Revenue$210.17M$210.17M+8.7% vs Q2 2011 Net Income$8.51M$8.51M+1,118.0% vs Q2 2011 EPS Diluted$0.30$0.30+1,400.0% vs Q2 2011 Gross Profit$131,896,000+9.5% Operating Income$18,021,000+125.3% Operating Cash Flowderived
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Integra Lifesciences Holdings Corp · CIK 917520 · Engraved from SEC EDGAR
Free Cash Flowderived-$11,954,000N/M Margins · derivedGross margin62.8%+0.4 pt vs Q2 2011
Operating margin8.6%+4.4 pt vs Q2 2011
Net margin4.1%+3.7 pt vs Q2 2011